<DOC>
	<DOCNO>NCT00876460</DOCNO>
	<brief_summary>To confirm safety BIBF 1120 dose level 200 mg x 2/day ( i.e. , overseas recommend Phase III dose combination treatment ) standard therapy docetaxel ( 60 mg/m2 75 mg/m2 ) Japanese advanced non small cell lung cancer ( NSCLC ) patient stage IIIB/IV recurrent failure first line chemotherapy determine recommend dose Phase II trial .</brief_summary>
	<brief_title>BIBF 1120 + Docetaxel ( Japan ) Patients With Advanced Non-small-cell Lung Cancer , Phase I</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Nintedanib</mesh_term>
	<criteria>Inclusion criterion : 1 . Histologically/cytologically confirm , locally advanced/metastatic NSCLC stage IIIB/IV recurrent NSCLC ( histology . Existence nonexistence measurable lesion accord RECIST object . ) 2 . Patients one prior chemotherapy regimen include platinumcontaining drug . In case recurrent disease , one additional prior regimen allow adjuvant and/or neoadjuvant therapy . However monotherapy EGFRTKI ( i.e . erlotinib/Tarceva® gefitinib/Iressa® ) count 'one regimen ' . 3 . Male female patient age &gt; =20 year = &lt; 74 year enrolment . 4 . Life expectancy least three ( 3 ) month start administration investigational drug . 5 . Eastern Cooperative Oncology Group ( ECOG ) [ R010787 ] performance Score 0 1 . 6 . Patients retain significant physiological compensatory function patient sufficient baseline organ function follow : Haemoglobin count 9.0g/dL Absolute neutrophil count 1500/mm3 Platelet count 100 000/mm3 Serum creatinine less equal to1.5x upper limit normal range investigator site Aspartate aminotransferase ( AST ) / alanine aminotransferase ( ALT ) less equal 1.5x upper limit normal range investigator site ( It patient liver metastasis ) PaO2 SpO2 60torr 92 % 7 . Written inform consent consistent ICHGCP guideline . Exclusion criterion : 1 . Patients receive chemotherapy ( include investigational drug ) , hormonal therapy immune therapy = &lt; 4 week prior registration recover side effect therapy . 2 . Patients receive radiotherapy = &lt; 4 week ( limited field ( e.g brain bone metastasis ) radiation = &lt; 2 week ) prior registration . 3 . Patients active brain metastasis . ( Patients symptom need receive therapy registration may participate trial ) 4 . Patients active double cancer . ( Patients skin cancer malignant melanoma carcinoma situ uterine cervix may participate trial ) 5 . Patients distinct / suspect pulmonary fibrosis interstitial lung disease chest radiographic finding , patient previous history . 6 . History clinically significant haemoptysis within past 3 month ( one tea spoon fresh blood per day ) 7 . Therapeutic anticoagulation ( except low dose heparin and/or heparin flush need maintenance indwell intravenous device ) antiplatelet therapy ( except chronic lowdose therapy acetylsalicylic acid = &lt; 325 mg per day ) 8 . History major thrombotic clinically relevant major bleed event past 6 month prior registration . 9 . Known inherited predisposition bleed thrombosis . 10 . Significant cardiovascular disease . ( i.e . hypertension control medical therapy , unstable angina , history myocardial infarction within past 6 month , congestive heart failure &gt; NYHA II , serious cardiac arrhythmia , pericardial effusion ) 11 . Significant weight loss ( &gt; 10 % ) within past 6 week prior registration trial 12 . Current peripheral neuropathy &gt; = CTCAE grade 2 except due trauma . 13 . Accumulation coelomic fluid ( e.g . pleural effusion , ascites fluid , cardiac effusion ) require treatment 14 . Major injury and/or surgery within past 10 day prior registration incomplete wound heal . 15 . Serious infection require systemic antibiotic ( e.g antiviral , antimicrobial , antifungal ) therapy . 16 . Decompensated diabetes mellitus contraindication high dose corticosteroid therapy . 17 . Gastrointestinal disorder abnormality ( e.g Crohn 's disease , Colitis ulcerosa extensive gastrectomy ) would interfere absorption study drug . 18 . Patients difficulty swallow study medication 19 . Patients positive HBs antigen , HCV antibody , HIV antibody test 20 . Serious illness concomitant nononcological disease neurologic , psychiatric , infectious disease active ulcer ( gastrointestinal tract , skin ) laboratory abnormality may increase risk associate trial participation investigational drug administration judgment investigator would make patient inappropriate entry trial . 21 . Patients sexually active unwilling use medically acceptable method contraception ( e.g . implant , injectables , combine oral contraceptive , intrauterine device vasectomize partner participate female , condom participate male ) trial least 12 month end active therapy 22 . Female patient pregnant , breast feeding may become pregnant . 23 . Patients suspect active alcohol drug abuse . 24 . Patient clinically meaningful drug hypersensitivity . 25 . Patients auto immune disease . 26 . Patients unable comply protocol . 27 . Other patient judge ineligible enrolment study investigator .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>